Early Treatment

Share |Pure speculation, based in part by POTUS’s rapid recovery and apparently greater success rates in under developed or what we thought of as under developed countries in treating COV-2

Our reluctance to use unapproved off label therapies in the treatment of COVID19 in the US, seems both endemic and contra intuitive. The guidelines published by the NEJM limit initiation of remdesevir to patients requiring high flow rate oxygen. Physicians have been sanctioned for advancing off label treatments, and I wonder how patient care came to depend on bureaucratic permission. Furthermore, Science Published an article suggesting dysfunctional FDA approval processes and questionable studies causing major delays.

Clinical medicine often conflicts with Public Health interests, and the treatment phase of this pandemic may be such a conflict with the, can I say, less respected health care and public health authority. Have we failed to make the transition from public health measures to serious aggressive individual patient care?